| Ashley Elizabeth Brim, CCC-SLP | |
|
208 Alton Sq, Alton, IL 62002-5919 | |
| (618) 463-5171 | |
| Not Available |
| Full Name | Ashley Elizabeth Brim |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 208 Alton Sq, Alton, Illinois |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1588179261 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | 146014349 (Illinois) | Primary |
| Provider Name | Onr National Speech Pathology Inc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1972965952 PECOS PAC ID: 2668463522 Enrollment ID: O20160831002993 |
News Archive
Delaying second doses of COVID-19 vaccines should reduce case numbers in the near term.
Results from the FUTURA/OASIS 8 study presented today at the ESC Congress provide initial evidence that a low dose of unfractionated heparin does not reduce the incidence of bleeding or vascular complications in PCI patients treated with the anticoagulant fondaparinux. Findings showed that the rates of peri-PCI major bleeding were 1.4% in those given low dose heparin and 1.2% the standard dose.
Repligen Corporation today reported results for the second quarter of fiscal year 2011, ended September 30, 2010.
Bone marrow stem cells suspended in X-ray-visible microbubbles dramatically improve the body's ability to build new blood vessels in the upper leg-providing a potential future treatment for those with peripheral arterial disease or PAD, say researchers at the Society of Interventional Radiology's 35th Annual Scientific Meeting in Tampa, Fla.
Prostate tumors that carry a "signature" of four molecular markers have the potential to become dangerously metastatic if not treated aggressively, researchers at Dana-Farber Cancer Institute report in a study published online today by the journal Nature. The discovery lays the groundwork for the first gene-based test for determining whether a man's prostate cancer is likely to remain dormant within the prostate gland, or spread lethally to other parts of the body.
› Verified 6 days ago
| Provider Name | Empowerme Rehabilitation Illinois Llc |
|---|---|
| Provider Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Provider Identifiers | NPI Number: 1679098263 PECOS PAC ID: 2365718277 Enrollment ID: O20171020001353 |
News Archive
Delaying second doses of COVID-19 vaccines should reduce case numbers in the near term.
Results from the FUTURA/OASIS 8 study presented today at the ESC Congress provide initial evidence that a low dose of unfractionated heparin does not reduce the incidence of bleeding or vascular complications in PCI patients treated with the anticoagulant fondaparinux. Findings showed that the rates of peri-PCI major bleeding were 1.4% in those given low dose heparin and 1.2% the standard dose.
Repligen Corporation today reported results for the second quarter of fiscal year 2011, ended September 30, 2010.
Bone marrow stem cells suspended in X-ray-visible microbubbles dramatically improve the body's ability to build new blood vessels in the upper leg-providing a potential future treatment for those with peripheral arterial disease or PAD, say researchers at the Society of Interventional Radiology's 35th Annual Scientific Meeting in Tampa, Fla.
Prostate tumors that carry a "signature" of four molecular markers have the potential to become dangerously metastatic if not treated aggressively, researchers at Dana-Farber Cancer Institute report in a study published online today by the journal Nature. The discovery lays the groundwork for the first gene-based test for determining whether a man's prostate cancer is likely to remain dormant within the prostate gland, or spread lethally to other parts of the body.
› Verified 6 days ago
| Provider Name | Empowerme Wellness Kansas City Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1174118103 PECOS PAC ID: 9830504836 Enrollment ID: O20210317001954 |
News Archive
Delaying second doses of COVID-19 vaccines should reduce case numbers in the near term.
Results from the FUTURA/OASIS 8 study presented today at the ESC Congress provide initial evidence that a low dose of unfractionated heparin does not reduce the incidence of bleeding or vascular complications in PCI patients treated with the anticoagulant fondaparinux. Findings showed that the rates of peri-PCI major bleeding were 1.4% in those given low dose heparin and 1.2% the standard dose.
Repligen Corporation today reported results for the second quarter of fiscal year 2011, ended September 30, 2010.
Bone marrow stem cells suspended in X-ray-visible microbubbles dramatically improve the body's ability to build new blood vessels in the upper leg-providing a potential future treatment for those with peripheral arterial disease or PAD, say researchers at the Society of Interventional Radiology's 35th Annual Scientific Meeting in Tampa, Fla.
Prostate tumors that carry a "signature" of four molecular markers have the potential to become dangerously metastatic if not treated aggressively, researchers at Dana-Farber Cancer Institute report in a study published online today by the journal Nature. The discovery lays the groundwork for the first gene-based test for determining whether a man's prostate cancer is likely to remain dormant within the prostate gland, or spread lethally to other parts of the body.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ashley Elizabeth Brim, CCC-SLP 4338 Piasa Rd, Brighton, IL 62012-2328 Ph: (618) 402-0438 | Ashley Elizabeth Brim, CCC-SLP 208 Alton Sq, Alton, IL 62002-5919 Ph: (618) 463-5171 |
News Archive
Delaying second doses of COVID-19 vaccines should reduce case numbers in the near term.
Results from the FUTURA/OASIS 8 study presented today at the ESC Congress provide initial evidence that a low dose of unfractionated heparin does not reduce the incidence of bleeding or vascular complications in PCI patients treated with the anticoagulant fondaparinux. Findings showed that the rates of peri-PCI major bleeding were 1.4% in those given low dose heparin and 1.2% the standard dose.
Repligen Corporation today reported results for the second quarter of fiscal year 2011, ended September 30, 2010.
Bone marrow stem cells suspended in X-ray-visible microbubbles dramatically improve the body's ability to build new blood vessels in the upper leg-providing a potential future treatment for those with peripheral arterial disease or PAD, say researchers at the Society of Interventional Radiology's 35th Annual Scientific Meeting in Tampa, Fla.
Prostate tumors that carry a "signature" of four molecular markers have the potential to become dangerously metastatic if not treated aggressively, researchers at Dana-Farber Cancer Institute report in a study published online today by the journal Nature. The discovery lays the groundwork for the first gene-based test for determining whether a man's prostate cancer is likely to remain dormant within the prostate gland, or spread lethally to other parts of the body.
› Verified 6 days ago
Mrs. Casey Ryan, MS, CF-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 550 Landmarks Blvd Ste A, Alton, IL 62002 Phone: 618-474-2600 | |
Mrs. Susan Margaret Curfman, MA, C.C.C. Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 915 E 5th St, Alton, IL 62002 Phone: 618-643-5230 Fax: 618-463-5366 | |
Mrs. Kara Wagner, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1513 State St, Alton, IL 62002 Phone: 618-463-2134 | |
Chelsi Christine Owens, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 815 E 5th St Ste 101, Alton, IL 62002 Phone: 618-463-5171 Fax: 618-463-5175 | |
Jenny Peppler, MS CCC/SLP Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 100 Glenhaven Dr, Alton, IL 62002 Phone: 618-462-1500 | |
Global Therapy Inc Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2710 College Ave Ste F, Alton, IL 62002 Phone: 618-530-7462 | |
Melanie Jo Whitmore, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1854 E Broadway, Alton, IL 62002 Phone: 618-474-2600 |